Stock Ratings / Health Care / APYX / financials

PYPD (44) SKYA (42) LUNG (39) NYXH (45) ⌘ Pro Terminal →

Apyx Medical Corporation (APYX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$2.60 -3.35% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.58

Apyx Medical Corporation (APYX) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $113.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on APYX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is APYX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Apyx Medical Corporation (NASDAQ: APYX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $2.60 (-3.35% 1D, market cap $113.3M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, APYX ranks #778 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does APYX compare to PYPD and SKYA in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), APYX carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 62.5%, and ROIC of -28.9%. By comparison, PYPD (PolyPid Ltd.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $113.5M) and SKYA (SkyAI Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $126.7M). Among the 5-stock peer group, APYX leads on earnings multiple (N/A) while APYX leads on capital efficiency (-28.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for APYX?

▼

Per APYX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000719135), Apyx Medical Corporation generated $52.8M in revenue (+9.9% YoY), -$11.2M in net income, and -$9.1M in free cash flow against $66.8M in total assets and $34.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.58 (-0.79%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-11.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for APYX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (32/100 Composite)

🔍 WHY APYX SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (38% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (22% of score)

FRED Regime × Technicals: 12% of 52W Range • RSI-14 at 49.1 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.59-1.5% Next Q

Q2 (-2Q)

Grade E$2.55-7.1% Next Q

Q3 (-1Q)

Grade E$2.37+9.7% Next Q

Current

Grade E$2.60-9.2% Hist 90D α

Trajectory: E (24) → E (32)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a APYX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While APYX currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.77) and Max Pain ($2.73) forces dealer call-delta covering toward $5.33.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $APYX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “APYX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 32%NO 68%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How APYX Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $52.3M

FY24

Rev $48.1M

FY25

Rev $52.8M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$52.8M	62.5%	-12.2%	-$11.2M	-$9.1M	-28.9%
FY 2024	$48.1M	61%	-39.2%	-$23.5M	-$18.8M	-45%
FY 2023	$52.3M	62.5%	-33%	-$18.7M	-$5.2M	-28.9%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring APYX)

✓Walkthrough of APYX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

APYX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -21.92%▼ DESCENDING CHANNEL

2026-10-30O $2.65H $2.65L $2.53C $2.60VOL 38.1K

RES: $3.27SUP: $1.89SMA50: $2.77SMA200: $3.60

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

APYX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 APYX Butterfly Map → + Track APYX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +9.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on APYX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for APYX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for APYX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (APYX)

Health Care Rank #778 of 1016 ⚔️ PYPD vs APYX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (APYX vs. PYPD, SKYA, LUNG, NYXH)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Apyx Medical Corporation (APYX) ranks #778 by composite RQD confidence (32/100, grade E) and #644 by equity capitalization ($113.3M). Within this direct 5-issuer industry benchmark cohort, APYX leads on earnings valuation at N/A trailing P/E, while APYX leads on capital efficiency and profitability with -28.9% ROIC and 62.5% gross margin. NYXH currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with APYX at 32/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
APYX ACTIVE Apyx Medical Corporation	E	32/100	—	62.5%	-28.9%	-3.35%	$113.3M	Benchmark Subject
PYPD PolyPid Ltd.	D	44/100	—	—	-35.0%	-3.58%	$113.5M	/pypd-vs-apyx →
SKYA SkyAI Inc.	D-	42/100	—	-30.0%	-35.0%	+1.37%	$126.7M	/skya-vs-apyx →
LUNG Pulmonx Corporation	D-	39/100	—	74.2%	-35.0%	-5.05%	$135.9M	/lung-vs-apyx →
NYXH Nyxoah SA	D	45/100	—	—	—	-1.85%	$88.9M	/nyxh-vs-apyx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000719135

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Apyx Medical Corporation (APYX) reported GAAP revenue of $52.8M (+9.9% vs. FY2024 revenue of $48.1M , and +0.9% cumulative change since FY2023) , GAAP net income of -$11.2M, operating cash flow of -$8.0M, and free cash flow of -$9.1M (+51.4% YoY). On the balance sheet, APYX closed FY2025 with $66.8M in total assets against $34.8M in total debt (Altman Z-Score: 0.75, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$52.8M	-$11.2M	-$8.0M	-$9.1M	$66.8M	$34.8M
FY2024 (FY)	2024-12-31	$48.1M	-$23.5M	-$18.0M	-$18.8M	$64.8M	$33.9M
FY2023 (FY)	2023-12-31	$52.3M	-$18.7M	-$5.2M	-$5.2M	—	—

3. APYX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is APYX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does APYX compare to PYPD and SKYA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for APYX?

Where is APYX trading relative to its 50-day, 200-day, and 52-week technical levels?

APYX last traded at $2.60 (-3.35% on volume of 38,095 shares), positioning the stock -6.14% below its 50-day simple moving average ($2.77) and -27.78% below its 200-day simple moving average ($3.60). Across its 52-week range of $2.25 to $5.08, APYX sits at the 12.4% percentile with a 14-day RSI of 49.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.27 to $2.93).

APYX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Apyx Medical Corporation (APYX)?

In FY 2025 (10-K), APYX converted $52.8M of revenue into a 62.5% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: APYX RQD Cockpit APYX 12M Forecast APYX Earnings & Move APYX Dividends & DRIP APYX Insiders & 13F APYX Whale Options APYX Profit Sankey APYX News & Why

ROARABLE RATING BRIEF • RQD 32/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

APYX — Apyx Medical Corporation: What the Facts Mean to a Prospective Investor

Engine: Haiku 5.5 Dossier Pipeline

As of: 2026-11-02T14:24Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD 5-pillar rating engine, Apyx Medical Corporation (APYX) carries a composite score of 32/100 (E — Roarable Strong Sell — Forensic Risk / Avoid) at a current price of $2.60 (-3.35%). Fundamental cash generation scores 4/20 (ROIC -28.9%, FCF yield -8.04%), institutional 13F whale accumulation scores 12/20, insider conviction scores 3/20, macro regime alignment scores 7/20 (Beta 1.00), and forensic balance-sheet protection scores 6/20 (Altman Z-Score 0.75, Piotroski F-Score 5/9).

Investor Implication: At current trailing P/E and current forward P/E within Medical/Dental Instruments, upside depends on sustained operating margin expansion (-12.2%) and free cash flow conversion relative to the 52-week range of $2.25 – $5.08.

Butterfly Effect: Supply-Chain, Sector & Catalyst Ripples

Operating in Medical/Dental Instruments (Health Care), APYX is sensitive to 2nd-order capital expenditure cycles, input cost spreads (gross margin 62.5%), and institutional positioning across its peer cohort. Prospective investors should monitor quarterly order backlog conversion, sector capex guidance, and Form 4 insider cluster activity (0 recent filings tracked).

Open Questions to Watch: (1) Margin trajectory vs. peer median; (2) FCF conversion sustainability over the next 4 quarters; (3) Institutional 13F rebalancing around upcoming earnings.

APYX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Apyx Medical Corporation (APYX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to APYX Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo • 11d ago

Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026

CLEARWATER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 12d ago

Apyx Medical Corporation to Participate in Upcoming Investor Conferences

CLEARWATER, Fla., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring Sy

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 34d ago

Apyx Medical Announces New Clinical Study Demonstrating Renuvion®’s Impact on Skin Quality

Patients reported high satisfaction and visible improvements in skin elasticity, youthfulness, and radianceCLEARWATER, Fla., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical” or th

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 39d ago

Cold Plasma Market Forecasts Growth from $3.32B (2025) to $8.45B by 2032, Profiling Nordson Corporation, Apyx Medical, Plasmatreat & Enercon Industries

Cold plasma offers opportunities in healthcare, food safety, agriculture, water treatment and manufacturing through chemical-free sterilization, surface engineering and AI-enabled automation.Dublin, Sept. 24, 2026 (GLOBE

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 48d ago

Cold Plasma Market Forecasts Growth from $167.8M (2025) to $495.9M by 2033, Profiling Apyx Medical, Neoplas Med, Adtec Healthcare & 5 Other Key Players

Cold plasma adoption is rising in healthcare for sterilization, wound healing and cancer care, with opportunities in infection control, food safety, textiles and eco-friendly processing.Dublin, Sept. 15, 2026 (GLOBE NEWS

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 80d ago

Apyx Medical (APYX) Q2 2026 Earnings Call Transcript

AYON adoption accelerated 22% as surgeons target GLP-1 weight-loss patients.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 82d ago

Apyx Medical Sees GLP-1 Boom Fueling Demand for Renuvion, AYON Body Contouring

Apyx Medical (NASDAQ:APYX) is positioning its Renuvion technology and newly launched AYON Body Contouring System to address growing demand for surgical aesthetic procedures, a trend CEO Charlie Goodwin said has been resh

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 87d ago

Apyx Medical Corp (APYX) (Q2 2026) Earnings Call Highlights: Revenue Surges 22% on Power Lipo ...

Company capitalizes on expanded FDA clearance and growing body contouring demand, reaffirming full-year guidance despite margin headwinds.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

APYX Bull vs. Bear Conversation Board — What's Your Call at $2.60?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON APYX 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $2.29 (-11.9%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is APYX (E • RQD 32/100) a Buy at $2.60?

Welcome to the APYX (Apyx Medical Corporation) Roar Pit. Current RQD Composite is 32/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.16 (-16.9%)

Spot @ $2.60

Pump the brakes on APYX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on APYX, but look at what you are paying: current EV/EBITDA multiples with 62.5% gross margins. Unless Apyx Medical Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $3.12 (+20.0%)

Spot @ $2.60

APYX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on APYX, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $2.60 (52-wk range $2.25 - $5.08), any beat on forward guidance forces shorts and underweight funds to chase.